All 149 Compounds in Development

DRUGS IN DEVELOPMENTEntry Inhibitors: 15D, Preclinical, National Cancer Institute 15K, Preclinical, National Cancer Institute Alpha defensins, Preclinical, CDC's AIDS, STD, and TB Laboratory Research AMD887 (CCR5 blocker), Preclinical, Anormed AMD3451 (CCR5-CXCR4 blocker), Preclinical, Anormed Aprepitant (NK-1R blocker), Preclinical, University of Pennsylvania Betulinic acid derivatives, Preclinical, University of North Carolina, Duke University, Vanderbilt University Bifunctional CCR5 and CD4 inhibitors, Preclinical, University of Regensburg CCR5mAb004 (CCR5 blocker), Phase I, Human Genome Sciences D5 (monoclonal antibody), Preclinical, Merck DP-178 (fusion inhibitor), Preclinical, Weizmann Institute GBV-C (chemokines, including CCR5 blockers), Preclinical, University of Iowa Genistein, Preclinical, Uniformed Services University of Health Sciences gp41 inhibitor, Preclinical, New York Blood Center gp41 inhibitor, Preclinical, Locus Pharmaceuticals gp120-gp41 disulfide bond, Preclinical, Amsterdam Mathematical Center, Cornell University, University of Illinois at Chicago HGS004 (CCR5 blocker, Phase I/II, Human Genome Sciences HGS101 (CCR5 blocker), Preclinical, Human Genome Sciences IC9564, Preclinical, Duke University INCB9471 (CCR5 blocker), Phase I/II, Incyte INCB15050, Preclinical, Incyte Indolicidin, Preclinical, National Institutes of Health KD-247 (CCR5 blocker), Preclinical, Kumamoto University KRH-3140 (CXCR4 blocker), Preclinical, Kureha KRH-3955 (CXCR4 blocker), Preclinical, Kureha MDX-010, Preclinical, Medarex Monoclonal FAbs (gp41 blocker), Preclinical, National Institutes of Health NB-2 (gp41 blocker), Preclinical, Shibo and Kumar NB-64 (gp41 blocker), Preclinical, Shibo and Kumar NSC 13778 (gp120 blocker), Preclinical, National Cancer Institute Peptidic CCR5 blocker, Preclinical, Selexis PF232798 (CCR5 blocker), Phase I, Pfizer PRO-140 (monoclonal antibody), Phase I/II, Progenics Pyrrolidine (CCR5 blocker), Preclinical, Merck RC-112, Preclinical, CDC's AIDS, STD, and TB Laboratory Research Retrocyclin-1, Preclinical, CDC's AIDS, STD, and TB Laboratory Research ROAb 12 (CCR5 blocker), Preclinical, Roche ROAb 13 (CCR5 blocker), Preclinical, Roche ROAb 14 (CCR5 blocker), Preclinical, Roche ROAb 18 (CCR5 blocker), Preclinical, Roche SCH-5327-6 (CCR5 blocker), Preclinical, Schering-Plough Sifuvirtide, Preclinical, Fusogen SP10A (entry inhibitor), Preclinical, Samaritan Suc-HSA (gp120 blocker), Phase I, Sanquin TAK-220 (CCR5 blocker), Phase 1, Tobira (licensed from Takeda) TAK-652 (CCR5 blocker), Phase I, Tobira (licensed from Takeda) TD0232, Preclinical, Avexa TNX-355 (monoclonal antibody), Phase II, Tanox and Biogen TR-999, Preclinical, Trimeris and Roche TR-1144, Preclinical, Trimeris and Roche UMIST, Preclinical, Genetic Innovation Network Vicriviroc (CCR5 blocker), Phase II, Schering-Plough ZFN (CCR5 blocker), Preclinical, Sangamo Biosciences Zing finger protein nucleases (CCR5 blockers), Preclinical, Sangamo Biosciences Integrase Inhibitors: AVX-I, Preclinical, Avexa Beta-diketo acids, Preclinical, University of Parma and University of Sassari Carbazole derivative, Preclinical, Japan's National Institute of Infectious Diseases Elvitegravir (GS-9137), Phase II, Gilead Sciences GS-9224, Preclinical, Gilead Sciences GSK-810871, Preclinical, GlaxoSmithKline GSK364735, Phase I, GlaxoSmithKline/Shionogi ITI-367, Preclinical, George Washington University L-second generation, Preclinical, Merck Monophores, Preclinical, Sunesis Mycelium integrasone fungal polyketide, Preclinical, Merck PL-2500, Preclinical, Procyon Biopharma Styrylquinoline derivatives, Preclinical, BioAlliance Pharma Theophylline, Preclinical, Thomas Jefferson University V-165, Preclinical, Rega Institute Maturation Inhibitors: Betulinic acid derivatives, Preclinical, University of North Carolina, Duke University, Vanderbilt University Bevirimat (PA-457) (gag processing inhibitor), Phase II, Panacos Capsid inhibitors, Preclinical, Achillion enJS56A1, (endogenous antiretroviral, Preclinical, University of Georgia PA1050040, (gag processing inhibitor), Phase 1, Panacos RPI-MN, (nAchR receptor inhibitor), Preclinical, ReceptoPharm Nonnucleoside Reverse Transcriptase Inhibitors: 70h (GW678248), Phase I, GlaxoSmithKline AR806, Preclinical, Ardea Biosciences BILR 355/r BS, Phase I/II, Boehringer Ingelheim C-8 quinolinyloxyethyl substitutent, Preclinical, Boehringer Ingelheim HBY097 (Pyridinone derivatives), Preclinical, Rutgers University Methyl derivatives, Preclinical, University of South Denmark MV026048, Preclinical, Medivir Oligodeoxinucleotides, Preclinical, University of Zurich PBO-15c (pyrrolobenzoxazepinone), Preclinical, University of Siena Phenylthiazoylamines, Preclinical, Yale University Rilpivirine (TMC-278), Phase II, Tibotec S-DABO derivatives, Preclinical, Fudan University SMP-610, Preclinical, Advanced Life Sciences SMP-717, Preclinical, Advanced Life Sciences Thiazol derivatives, Preclinical, Japan's Institute for Virus Research UK-435061, Phase I/II, Pfizer Nucleoside Reverse Transcriptase Inhibitors: 4-Ed4T, Preclinical, Kagoshima University Apricitabine (ATC), Phase I/II, Avexa ARC, Preclinical, Howard University BPH-218, Preclinical, University of Pittsburgh Branched 3 primers, Preclinical, University of Illinois Compound X, Preclinical, Tibotec D-FDOC, Preclinical, Emory University Didox ribonucleotide reductase inhibitor, Preclinical, University of Texas Dinucleoside polyphosphates, Preclinical, University of Miami DOT (dioxolane thymidine), Phase I, University of Georgia dTTP, Preclinical, University of Rochester E2-FdA, Preclinical, Kumamoto University Elvucitabine (ACH-126), Phase I/II, Achillion Fosalvudine (alovudine prodrug), Phase I/II, Heidelberg Pharmaceuticals GS-9131, Preclinical, Gilead Sciences Herpesvirus saimiri, Preclinical, Temple University IDX12899, Preclinical, Idenix Pharmaceuticals IDX12989, Preclinical, Idenix Pharmaceuticals KMMP05, Preclinical, National Cancer Institute Quinolones, Preclinical, Rega Institute R12-2, Preclinical, University of Texas Racivir, Phase I/II, Pharmasset Stampidine, Preclinical, Parker Hughes Institute Thiostavudine, Preclinical, Showa University Thiovir, Preclinical, Adventrx Triol, Preclinical, Cruz Foundation TSAO-T derivatives, Preclinical, University of Pittsburgh Protease Inhibitors A-681799, Preclinical, Abbott Laboratories Beta-lactam, Preclinical, University of Debrecen GRL-02031, Preclinical, Kumamoto University PPL-100, Phase I, Merck SPI-256, Preclinical, Sequoia SPI-452, Phase 1, Sequoia Pharmaceuticals UIC02031, Preclinical, Kumamoto University Other Classes: 1H4 (tat inhibitor), Preclinical, Taras Shevchenko University Alpha-V integrins, Preclinical, Merck BI-201 (tat inhibitor), Phase I, BioInvent BIT225 (Vpu ion blockers), Phase 1, Biotron Limited CNI-1493 (rev inhibitor), Preclinical, Optokine Pharmasciences Curcumin/diferuloylmethane (tat inhibitor), Preclinical, Jawaharlal Nehru Center Glycodendrimers (lipid raft carbohydrates), Preclinical, Penn State University Histone deacetylase inhibitors, Preclinical, University of California, San Francisco HRG214 (caprine IgG), Preclinical, Vironyx IM (CDK9 inhibitor), Preclinical, Institute of Human Virology KP-1461 (viral decay accelerator), Phase I/II, Koronis KU-55933 (ATM kinase inhibitor), Preclinical, Kudos Pharma LEDGF (integrase competers), Preclinical, Catholic University of Leuven MDI-P (electrolyzed free radical), Preclinical, Medical Discoveries Morpholino antisense oligonucleotides, Preclinical, AVI BioPharma Oxadiazols (nuclear localization viral matrix blockers), Preclinical, International Therapeutics Poly acrylic acid, Preclinical, Chinese Academy of Science Resveretol (Egr1 gene activator), Preclinical, National Cancer Institute Rev inhibitors, Preclinical, National Institutes of Health RPI (nicotinic acetylcholine receptor blocker), Preclinical, NutraPharma RSC-1838, Preclinical, GlaxoSmithKline and Shionogi RWJ67567 (p38 inhibitor), Preclinical, University of Pennsylvania SCY-635 (cyclophilin inhibitor), Preclinical, Scynexis siRNA constructs (rev/tat inhibitors), Preclinical, Beckman Institute siRNA, Preclinical, CombiMatrix TRIM5-alpha (capsid inhibitor), Preclinical, Dana-Farber Cancer Institute and the National Institute of Allergy and Infectious Diseases